Drugs Safety Labeling Updates
Drugs Safety Labeling Updates
| Scientific Name | Trade Name | Updated Section | Safety-Related Labeling Changes | Date |
|---|---|---|---|---|
| Larotrectinib | Vitrakvi | 4.8 Undesirable effects | Hepatotoxicity | Nov,2023 |
| Ibrutinib | Imbruvica | 4.8 Undesirable effects | Pyogenic granuloma and Acute kidney injury | Nov,2023 |
| Tadalafil | Cialis | 4.4 Special Warnings and Special Precautions for Use | Central Serous Chorioretinopathy | Nov,2023 |
| Paroxetine | Seroxat | 4.8 Undesirable effects | Leukopenia | Oct,2023 |
| Insulin Degludec,Liraglutide | Xultophy | 4.8 Undesirable effects | Ileus , angioedema, cholecystitism Elevations of liver enzymes, hyperbilirubinemia, cholestasis, hepatitis, Medullary thyroid carcinoma , Dysgeusia, dizziness , Increased serum creatinine, acute renal failure or worsening of chronic renal failure, sometimes requiring hemodialysis. | Oct,2023 |
| Liraglutide | Saxenda | 4.8 Undesirable effects | Ileus | Oct,2023 |